Clinical observation of gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients

VernacularTitle:吉西他滨联合卡铂治疗老年晚期非小细胞肺癌的临床观察
Author: Yingqiang TAN
Publication Type:Journal Article
Keywords: Careinoma,non-small cell lung; Gemcitabine; Carboplatin; Antineoplastic combined Chemothera-py protocols; Aged
From: Chinese Journal of Primary Medicine and Pharmacy 2008;15(10):1664-1665
CountryChina
Language:Chinese
Abstract: Objective To evaluate the clinical effect and safety of gemcitabine plus carboplatin regimen in the treatment of advanced non-small cell lung cancer(NSCLC) in aged patients. Methods 110 cases of aged patients with NSCLC , were divided into GEM group and NVB group according to the patients "options. GEM group received 1 000 mg/m2, GEM at day 1 and 8, and AUC 5 CBP at day 1. NVB group underwent the therapy of 2.5 mg/m2, NVB at day 1 and8,and 80 mg/m2 DDP at day 1 and 3. Both were treated with 21 days as a cycle. Results Overall re-sponse rate was 75.0% in GEM group and 72.0% in NVB group without significant difference( P>0.05). The medi-an survival time(MST) ,disease median response time(DPT) and one year survival rate were similar in two groups( P>0.05). The incidence of adverse reactions was significantly lower in GEM group than in NVB group ( P<0.05 ).Conclusion Gemcitabine plus carboplatin regimen is effective and safe in treatment of advanced non-small cell lung cancer in aged patients